PRGONYSEPharmaceutical PreparationsUS GAAP · USD

PERRIGO Co plc

Perrigo Co plc is a consumer self-care company focused on over-the-counter health and wellness products sold through retail and pharmacy channels. Its portfolio spans store-brand and branded products across North America and Europe, including infant formula, upper respiratory, nutrition, women’s health, oral care, skin care, and other everyday self-care categories.

Liikevaihto4 253milj. USD
−2,8 %v/v
Liikevoitto (EBIT)−1 122milj. USD
−1 094,0 %v/v
EBIT-marginaali−26,4%
−29,0 %-yks.v/v
Nettotulos−1 425milj. USD
−729,7 %v/v
Vapaa kassavirta145milj. USD
−40,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−2 00002 0004 0006 000milj. USD2020: 4 088 milj. USD2020: EBIT 265 milj. USD20202021: 4 139 milj. USD2021: EBIT 410 milj. USD20212022: 4 452 milj. USD2022: EBIT 79 milj. USD20222023: 4 656 milj. USD2023: EBIT 152 milj. USD20232024: 4 373 milj. USD2024: EBIT 113 milj. USD20242025: 4 253 milj. USD2025: EBIT −1 122 milj. USD20254 253−1 122
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Store-brand self-care45 %

Private-label OTC health products sold through retail and pharmacy customers.

Branded consumer health25 %

Consumer health brands sold under Perrigo-owned names in key markets.

Infant formula and nutrition15 %

Infant formula and related nutrition products sold in North America and other markets.

Women’s health and contraception5 %

Products such as emergency contraception and related women’s health items.

Skin care and topical treatments5 %

Products including skin care, wound care, and topical consumer health items.

Other self-care categories5 %

Additional OTC and wellness categories such as oral care and upper respiratory.

Asiakkaat

Perrigo sells primarily to large retail chains, mass merchants, pharmacies, and other consumer health distributors that stock store-brand and branded OTC products. End demand comes from consumers seeking affordable, accessible self-care products without a prescription, while Perrigo’s customers buy to fill shelf space, support category breadth, and offer value-priced alternatives. The company also serves a small number of large customers, with Walmart representing a significant share of sales in the latest reported year.

Large retail and mass merchant chains

They buy store-brand OTC products and branded consumer health items to support shelf assortment and value pricing.

Pharmacy and drugstore channels

They purchase OTC remedies and wellness products for prescription-adjacent and self-care aisles.

Consumer health distributors

They source branded and private-label products for regional or specialty retail distribution.

End consumers

They buy Perrigo-branded and store-brand products for everyday self-care needs and affordability.

Strategia

Perrigo’s strategy centers on consumer-led innovation, stronger branded and store-brand demand generation, and a more efficient global supply chain. The company also emphasizes portfolio focus, with capital and management attention directed toward categories and brands that can scale across geographies and channels. Its operating model is built to support value-priced self-care products while expanding adjacent categories and new product launches.

Consumer-led innovation and line extensionsLyhyt aikaväli

Keeps the portfolio relevant and supports shelf space with retail customers.

Portfolio focus on core self-care brandsKeskipitkä aikaväli

Concentrates resources on categories with stronger strategic fit and scale.

Supply chain and operating model efficiencyKeskipitkä aikaväli

A more efficient network supports service levels, cost control, and resilience.

Infant formula footprint optimizationLyhyt aikaväli

Manufacturing and quality improvements are intended to support this business line.

Maantiede

Q1/2026

Perrigo’s business is concentrated in North America and Europe, with those regions forming the core of its consumer self-care platform. North America is especially important for store-brand leadership and products such as Opill and Mederma, while Europe is anchored by brands including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. The company’s manufacturing, sourcing, and regulatory footprint spans multiple countries, so product availability and compliance depend on regional supply chains and local market rules.

USA57 %
Europe40 %
Other countries (US filing)2,4 %
Ireland0,4 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Perrigo faces the usual consumer health risks of competition, regulation, product quality, and raw-material volatility, but its business is also exposed to retail concentration and supply-chain disruption. Because many products are sold through a small number of large customers and manufactured through a global network, service failures, recalls, or logistics interruptions can quickly affect sales and reputation. The company also carries meaningful goodwill and impairment risk tied to category performance and portfolio changes.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Goodwill impairment1Customer concentration2Supply chain disruption3Regulatory and product quality risk4Raw material and input cost volatility5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Goodwill impairmentVaikutus: KorkeaTodennäköisyys: Korkea

    The company has large goodwill balances and uses impairment testing that can produce non-cash charges when expectations change.

    Kohdistuu: CSCA and CSCI reporting units

  2. Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A small number of large retailers account for a meaningful share of sales, so lost shelf space or weaker terms can hurt revenue.

    Kohdistuu: Walmart and other top customers

  3. Supply chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Global sourcing and manufacturing create exposure to plant outages, logistics issues, labor shortages, and geopolitical events.

    Kohdistuu: Manufacturing and distribution network

  4. Regulatory and product quality riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    OTC and infant formula products operate in regulated categories where compliance or safety issues can stop shipments or damage trust.

    Kohdistuu: Self-care and infant formula portfolios

  5. Raw material and input cost volatilityVaikutus: KeskitasoTodennäköisyys: Korkea

    Ingredient and packaging costs can move quickly and are difficult to fully pass through in retail channels.

    Kohdistuu: OTC formulations and packaging

Kirjanpito

Harkinnanvaraiset erät
Goodwill impairment

Impairment tests depend on fair value, cash-flow, and market assumptions; changes can trigger large charges.

Vaikutus: CSCA and CSCI goodwill balances and earnings

Held-for-sale classification

Businesses under strategic review or divestiture are reclassified and measured differently.

Vaikutus: Asset presentation and disposal gains/losses

Inventory and reserves

Consumer health products require estimates for obsolescence, returns, and quality-related provisions.

Vaikutus: Gross margin and working capital

Revenue recognition and customer allowances

Retail sell-in, rebates, and returns can affect the timing and amount of recognized revenue.

Vaikutus: Quarterly sales comparability

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

PERRIGO Co plc (PRGO) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo